High N‐terminal pro–brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis
Open Access
- 28 December 2007
- journal article
- systemic sclerosis
- Published by Wiley in Arthritis & Rheumatism
- Vol. 58 (1) , 284-291
Abstract
Objective: To evaluate predictors of pulmonary arterial hypertension (PAH) in a prospective cohort of patients with systemic sclerosis (SSc).Methods: Routine clinical assessments as well as measurements of the diffusing capacity for carbon monoxide/alveolar volume (DLCO/VA) ratio and N‐terminal pro–brain natriuretic peptide (NT‐proBNP) level were performed in a prospective cohort of 101 SSc patients who did not have PAH or severe comorbidities. After a planned 36‐month followup, we evaluated the predictive value of these parameters for the development of precapillary PAH, as demonstrated by cardiac catheterization, disease progression, and death. Criteria for cardiac catheterization were a systolic pulmonary artery pressure (PAP) of >40 mm Hg on echocardiography, a DLCO value of P < 0.01 for each comparison), elevated plasma NT‐proBNP level (>97th percentile of normal; P = 0.005), echocardiographically estimated systolic PAP >40 mm Hg (P = 0.08), and erythrocyte sedimentation rate >28 mm/hour (P = 0.015). In multivariate analyses, an elevated baseline NT‐proBNP level (hazard ratio [HR] 9.97 [95% confidence interval (95% CI) 1.69–62.42]) and a DLCO/VA ratio <60% (HR 36.66 [95% CI 3.45–387.6]) were predictors of the occurrence of PAH during followup. An increased NT‐proBNP level together with a decreased DLCO/VA ratio of <70% was highly predictive of the occurrence of PAH during followup (HR 47.20 [95% CI 4.90–450.33]).Conclusion: This prospective study identified a decreased DLCO/VA ratio and an increased NT‐proBNP as predictors of PAH in SSc. Use of these markers should result in improved PAH risk stratification and allow earlier initiation of therapy.Keywords
This publication has 26 references indexed in Scilit:
- Pulmonary arterial hypertension and rheumatic diseases—from diagnosis to treatmentRheumatology, 2006
- N-Terminal Pro-B-Type Natriuretic Peptide as an Indicator of Disease Severity in a Heterogeneous Group of Patients With Chronic Precapillary Pulmonary HypertensionThe American Journal of Cardiology, 2006
- Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertensionEuropean Heart Journal, 2006
- Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routineHeart, 2005
- N‐terminal pro–brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium‐channel blockersArthritis & Rheumatism, 2003
- Age and Risk of Pulmonary Arterial Hypertension in Scleroderma*Chest, 2003
- Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertensionRespiratory Medicine, 2003
- Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approachAnnals of the Rheumatic Diseases, 2003
- Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvementArthritis & Rheumatism, 2003
- Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survivalRheumatology, 2001